http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 12 Jan 2026 07:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Haisco+Grants+Global+Rights+of+Innovative+Drug+HSK39004+to+AirNexis+in+Deal+Exceeding+USD+1+Billion/25833831.html <div class="xn-content"> <p class="prntac">HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities</p><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- On <chron>January 9, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with US based biotech AirNexis. Under the agreement, Haisco grants AirNexis the rights to develop, manufacture, and commercialize its independently developed innovative drug HSK39004 globally, excluding Greater China. The total deal value reaches up to <money>USD 1.063 billion</money>, including an upfront payment of <money>USD 108 million</money> (<money>USD 40 http://www.streetinsider.com/Press+Releases/Haisco+Grants+Global+Rights+of+Innovative+Drug+HSK39004+to+AirNexis+in+Deal+Exceeding+USD+1+Billion/25833831.html Mon, 12 Jan 2026 07:00:00 -0500 002653 O.13064183 http://www.streetinsider.com/PRNewswire/Haisco+Grants+Global+Rights+of+Innovative+Drug+HSK39004+to+AirNexis+in+Deal+Exceeding+USD+1+Billion/25833831.html <div class="xn-content"> <p class="prntac">HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities</p><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- On <chron>January 9, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with US based biotech AirNexis. Under the agreement, Haisco grants AirNexis the rights to develop, manufacture, and commercialize its independently developed innovative drug HSK39004 globally, excluding Greater China. The total deal value reaches up to <money>USD 1.063 billion</money>, including an upfront payment of <money>USD 108 million</money> (<money>USD 40 http://www.streetinsider.com/PRNewswire/Haisco+Grants+Global+Rights+of+Innovative+Drug+HSK39004+to+AirNexis+in+Deal+Exceeding+USD+1+Billion/25833831.html Mon, 12 Jan 2026 07:00:00 -0500 002653 O.13064183 http://www.streetinsider.com/Press+Releases/Haisco+Grants+Global+Rights+of+Innovative+Drug+HSK39004+to+AirNexis+in+Deal+Exceeding+USD+1+Billion/25833831.html <div class="xn-content"> <p class="prntac">HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities</p><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- On <chron>January 9, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with US based biotech AirNexis. Under the agreement, Haisco grants AirNexis the rights to develop, manufacture, and commercialize its independently developed innovative drug HSK39004 globally, excluding Greater China. The total deal value reaches up to <money>USD 1.063 billion</money>, including an upfront payment of <money>USD 108 million</money> (<money>USD 40 http://www.streetinsider.com/Press+Releases/Haisco+Grants+Global+Rights+of+Innovative+Drug+HSK39004+to+AirNexis+in+Deal+Exceeding+USD+1+Billion/25833831.html Mon, 12 Jan 2026 07:00:00 -0500 002653 O.13064183 http://www.streetinsider.com/PRNewswire/Haisco+Grants+Global+Rights+of+Innovative+Drug+HSK39004+to+AirNexis+in+Deal+Exceeding+USD+1+Billion/25833831.html <div class="xn-content"> <p class="prntac">HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities</p><p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- On <chron>January 9, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with US based biotech AirNexis. Under the agreement, Haisco grants AirNexis the rights to develop, manufacture, and commercialize its independently developed innovative drug HSK39004 globally, excluding Greater China. The total deal value reaches up to <money>USD 1.063 billion</money>, including an upfront payment of <money>USD 108 million</money> (<money>USD 40 http://www.streetinsider.com/PRNewswire/Haisco+Grants+Global+Rights+of+Innovative+Drug+HSK39004+to+AirNexis+in+Deal+Exceeding+USD+1+Billion/25833831.html Mon, 12 Jan 2026 07:00:00 -0500 002653 O.13064183